ENvue Medical Inc

ENvue Medical Inc(FEED)の株式分析

$1.030

-0.713 (-69.25%)終値時点

Loading chart…
高値
3.420
始値
3.340
出来高加重平均価格
1.76
出来高
1.22M
時価総額
—
安値
0.840
売買代金
2.16M
EV/EBITDA(TTM)
0.00

ENvue Medical, Inc. is a medical technology company advancing both non-invasive and minimally invasive solutions across clinical and home care settings. Its segments include NanoVibronix, ENvue and Corporate. NanoVibronix is engaged in selling its products directly to patients as well as through distributor agreements. ENvue is engaged in selling its systems and Nasoenteral tubes and related services. The Company focuses on two distinct technology platforms: Acoustic-based therapeutic technologies, including PainShield and UroShield, which utilize proprietary low-intensity surface acoustic wave (SAW) technology. These devices are intended for use in home or care settings and are designed to treat pain, reduce bacterial colonization, and disrupt biofilms. The ENvue Navigation Platform, which is a minimally invasive electromagnetic navigation system intended to assist clinicians in placing feeding tubes into the gastrointestinal tract.

envuemed.com

AI分析 of ENvue Medical Inc (FEED)

売り

ENvue Medical, Inc. (FEED) is not a good buy right now due to its extremely low price of $1.03, a staggering year-to-date change of -96.50%, and an RSI of 7.252 indicating oversold conditions. The company has also reported a gross margin of -111.30% in Q2 2026, highlighting severe profitability issues. The main risk is its recent performance, with a 5-day change of -75.93%, indicating continued downward pressure on the stock.

バリュエーション指標

ENvue Medical Inc(FEED)の現在の予想PERは0.00で、5年平均は-0.00です。

予想PER

大幅な割高
5年平均 P/E
-0.00
現在のP/E
0.00
割高
-0.00
割安
-0.00

予想EV/EBITDA

大幅な割安
5年平均 EV/EBITDA
0.00
現在のEV/EBITDA
0.00
割高
0.00
割安
0.00

予想PSR

大幅な割安
5年平均 P/S
0.88
現在のP/S
0.00
割高
1.04
割安
0.72

イベントタイムライン

2026-10-29 (ET)

08:00:00

ENvue Medical Begins UroShield Production in the U.S.

2026-10-26 (ET)

08:00:00

ENvue Medical CEO Emphasizes Profitability Goals and Market Expansion

2026-09-15 (ET)

13:00:00

ENvue Medical's Nasdaq Listing Request Denied

2026-09-09 (ET)

09:30:00

ENvue Medical Resumes Commercial Shipments of PainShield

2026-08-10 (ET)

16:30:00

ENvue Medical Files $50M Mixed Securities Shelf

ニュース

FEED のよくある質問 — Alphio AI が回答

ENvue Medical, Inc. is a medical technology company advancing both non-invasive and minimally invasive solutions across clinical and home care settings. Its segments include NanoVibronix, ENvue and Corporate. NanoVibronix is engaged in selling its products directly to patients as well as through distributor agreements. ENvue is engaged in selling its systems and Nasoenteral tubes and related services. The Company focuses on two distinct technology platforms: Acoustic-based therapeutic technologies, including PainShield and UroShield, which utilize proprietary low-intensity surface acoustic wave (SAW) technology. These devices are intended for use in home or care settings and are designed to treat pain, reduce bacterial colonization, and disrupt biofilms. The ENvue Navigation Platform, which is a minimally invasive electromagnetic navigation system intended to assist clinicians in placing feeding tubes into the gastrointestinal tract. It operates in the Healthcare sector.

ENvue Medical, Inc. (FEED) is not a good buy right now due to its extremely low price of $1.03, a staggering year-to-date change of -96.50%, and an RSI of 7.252 indicating oversold conditions. The company has also reported a gross margin of -111.30% in Q2 2026, highlighting severe profitability issues. The main risk is its recent performance, with a 5-day change of -75.93%, indicating continued downward pressure on the stock.

コミュニティ

もっと見る ↗

投稿はまだありません

登録またはログインして議論に参加

関連記事

本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。

取引を始める